Paul Kaufman, MD

Wisconsin Regional Primate Research Center, Animal Health and Biomedical Sciences - School of Veterinary Medicine, Director-Glaucoma Services

M.D. 1967, New York School of Medicine, NY

Bellevue Hospital, New York, NY

Washington University School of Medicine and Barnes Hospital, St. Louis, MO

Ocular Pharmacology Fellowship, Seeing Eye and National Institutes of Health Research Fellow, Departments of Pharmacology and Physiology, University of Uppsalla, Uppsala, Sweden

My research centers on studies of the physiology, pharmacology, morphology, cell biology, genetic manipulation, neural control, biomechanics and aging of the aqueous humor formation and drainage and accommodative mechanisms in the non-human primate, seeking to understand the pathophysiology and develop new therapies for the human diseases of glaucoma and presbyopia.

Glaucoma is the second most common cause of irreversible visual loss in adult Americans, the most common among African Americans, and the most common world-wide, while presbyopia is the most common of all ocular afflictions.

Structure/Function Studies and the Effects of Memantine in Monkeys with Experimental Glaucoma.
March 20, 2012

1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates.
December 27, 2011

Cytoskeletal drugs prevent posterior capsular opacification in human lens capsule in vitro.
December 6, 2011

Glaucoma Research Community and FDA Look to the Future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: Measures of Structural Change and Visual Function.
October 6, 2011

Relationship of Aqueous Outflow Resistance to Age and Total Volume Perfused in Rhesus and Cynomolgus Monkeys.
July 16, 2011

Evaluation of rebound tonometry in non-human primates.
February 15, 2011